PhRMA escalated legal challenges to the Trump administration’s drug-pricing demo program, pushing back on Medicare “most-favored nation” concepts. In separate filings, the trade group argues the GLOBE pilot exceeds Medicare’s statutory authority, even as the administration’s structure exempts most companies through voluntary arrangements linked to Medicaid MFN pricing. The dispute arrives as tariff and pricing moves are increasingly intertwined with supply chains and compliance planning for branded drugs and active ingredients. For biotech sponsors—especially smaller companies without large manufacturing footprints—pricing and tariff uncertainty is translating into tighter capital allocation and more complex commercialization pathways. Regulators and courts will likely become a key determinant of near-term cash-flow assumptions for companies reliant on U.S. market access and pricing frameworks.